Incannex Healthcare announces a positive Pre-Investigational New Drug Application meeting with the FDA concerning IHL-42X, a compound for treating sleep apnoea.
Articles
MindMed Reports First Quarter 2022 Financial Results and Business Highlights
MindMed reports results for Q1 2022. Progress on clinical trials. Used $12.9 million cash in previous quarter. Cash balance of $120.5 million as of March 31, 2022.
Awakn Life Sciences Appoints UK Leader in Addictions Psychiatry, Dr. Arun Dhandayudham, as Chief Medical Officer
Awakn Life Sciences announces the appointment of noted expert in addictions psychiatry, Dr. Arun Dhandayudham as its new CMO.
Optimi Health Acquires Extensive Catalog of Psychedelic and Functional Mushroom Genetics
Optimi Health announces the acquisition of a diverse catalogue of psilocybin and functional mushroom strains intended for cultivation.
atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update
atai Life Sciences reports Q1 for 2022: clinical trials advancing and cash position of $335 million.
Major Step Forward For PTSD Treatment And The Psychedelics Industry
A new partnership between the U.S. Veterans Administration and Delic Holdings is ushering in a new era for PTSD treatment in the U.S. military.
Red Light Holland Successfully Imports 200 Psilocybin iMicrodose Packs, Sold in The Netherlands, Into Canada Under a Third Health Canada Approved Psilocybin Import Permit To cGMP Laboratory
Red Light Holland announces successfully importing its psilocybin microdose packs from the Netherlands into Canada.
Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment
Numinus Wellness announces Health Canada approval of its application to use psilocybin-assisted therapy for treatment-resistant depression (TRD).
DELIC HOLDINGS CORP PROVIDES DEFAULT STATUS UPDATE
Delic Holdings announces that it will miss its deadline under Canadian Securities Law to file its audited financial results. As a results, a Management Cease Trade Order (MCTO) has been issued.
Field Trip and Nue Life Are Collaborating To Bring Psychedelic Therapy Into the Home
Field Trip launches a telehealth version of its ketamine-assisted therapy, via a partnership with Nue Life Health.
Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014
Mindset Pharma announces initial planning of its Phase 1 clinical trials for its first family of novel molecules.
Ketamine Wellness Centers Announces Partnership With The Veterans Administration (VA) in Arizona
Delic Holdings subsidiary, Ketamine Wellness Centers (KWC) announces a partnership with the Veterans Administration to provide ketamine-assisted therapy for veterans with PTSD.
MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management
MindMed announces it will host a webinar on substance abuse disorders and withdrawal management that includes prominent experts in this field.
Revitalist’s Strategic Initiatives Continue to Exceed Expectations for Execution Giving Company Record High Revenues Since Opening in 2018.
Revitalist Lifestyle and Wellness reports strong month-over-month and year-over-year revenue gains from its ketamine clinic operations.
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
Mind Medicine Inc announces strong clinical results from its Phase 2 clinical trial using MM-120 for the treatment of Generalized Anxiety Disorder (GAD).